|
|
Profile
|
Delegates :
Yo Amakusa |
|
Incorporated :
February 1 , 2018 |
Paid in Capital :
100 Million yen |
Employees :
13 人 |
Address :
Nagoya Life Science Incubator (NALIC) #417 2-22-8, Chikusa, Chikusa-ku, Nagoya, AICHI
〒464-0858
|
TEL/FAX :
+81-52-753-8654 / +81-52-753-8658 |
URL：
https://www.ibody.co.jp/en/ |
Attachment :
 Ojima-Kato_et_al.,_Sci._Rep,_7,_13979_(2017).pdf [ 1.6MiB ] |
Mission/Background :
iBody is a start-up company from the Nagoya University of Japan.
Our unique platform, "Ecobody" technology that integrates single-cell and cell-free antibody expression technologies, enable us to rapidly (2 days) and efficiently generate highly functional monoclinal antibodies from humans, rabbits and alpacas.
The primary business of iBody is generating monoclonal antibodies for challenging targets as contract service and collaborative research with pharmaceutical and diagnostic drug companies.
Mission: Contributing to the development of diagnostics and therapeutics using innovative antibody exploration technology.
Vision: We are the only antibody company worldwide that accelerates innovation and continues to deliver antibodies that are difficult to obtain with other technologies.
Keywords: monoclonal antibody, custom monoclonal antibody, rabbit, human, monoclonal antibody generating service. |
|
Technology & Business
|
Platform technology
With “Ecobody” technology that integrates single-cell technology and cell-free antibody expression technology, we exhaustively and rapidly obtain and evaluate monoclonal antibodies from single B cells of humans, rabbits, and other animals without missing useful antibodies.
Patent
① Protein expression method
・Japan: Patent No. 6681625
・USA: Patent No. 10975376
・Europe: Patent No. 3312278
②Antibody with Tag
Japan: Patent No. 6744670
About Our Business
・Monoclonal Antibody Generating Service, Collaborative Research
iBody provides a monoclonal antibody generating service to researchers in pharmaceutical and diagnostic drug companies and academics who need highly functional monoclonal antibodies that are difficult to obtain using conventional technologies.
・Discovery and Development of Novel Antibody Therapeutics
We are working on the discovery and development of new antibody therapeutics based on collaborative researches with academics.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Monoclonal Antibody Generating Service
|
Launched
|
Generating monoclonal antibodies from human, rabbit, and other animals. Contingency Fee Plan is also available.
|
Expansion of services, Development of overseas markets, Technological improvement
|
Monoclonal Antibody Generating through Collaborative Research
|
Launched
|
Working on generating more difficult-to-generate monoclonal antibodies through collaborative research.
|
Technological improvement
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
On January 2025, our core technology, the protein expression method, has been granted a European patent.
On October 2024, we started the collaborative research project with Professor Kouhei Tsumoto of Tokyo University Graduate School on humanization technology of rabbit monoclonal antibodies.
On January 2023, we established the strategic business and capital alliance with TAUNS Laboratories one of Japan’s leading companies in the in vitro diagnostics field in Japan and we raised 300 million yen.
|
|
Hot news
|
On June 2024, A new antigen test kit for COVID-19 developed using monoclonal antibodies obtained with our Ecobody technology, was launched by our capital business partner, TAUNS Laboratories Inc.
|
|
Alliance strategy
|
Please feel free to contact us if you have any issues with monoclonal antibody generating for drug discovery, diagnosis drug development and research tools.
Contact Information: https://www.ibody.co.jp/en/contact/
|
|
|